

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re Patent Application of

Avraham Cohen et al.

Application No.: 10/561,844

Filing Date: December 22, 2005

Title: MONOHYDRATED SODIUM SALT OF
S-TENATOPRAZOLE AND THE USE
THEREOF IN THERAPY



Group Art Unit:

Examiner:

Confirmation No.: 5513

FIRST
INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a FIRST Information Disclosure Statement (IDS) and accompanying form PTO-1449 for the above-identified patent application.

- ☒ No additional fee for submission of an IDS is required.
- ☐ The fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e) is also enclosed.
- ☐ A statement under 37 C.F.R. § 1.97(e), and the fee of \$ 180 as set forth in 37 C.F.R. § 1.17(p) are also enclosed.
- ☐ Charge _____ to Deposit Account No. 02-4800 for the fee due.
- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☐ Charge _____ to credit card for the fee due. Form PTO-2038 is attached.
- ☒ The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date February 5, 2007

By: Melissa M. Hayworth

Melissa M. Hayworth
Registration No. 45774

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.


The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. § 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No.02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: February 5, 2007

By:


Melissa M. Hayworth
Registration No. 45774

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620

FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number

10/561,844

Filing Date

December 22, 2005


First Named Inventor

Avraham COHEN et al

Examiner Name

Attorney Docket Number

1032013-000133



U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
	2 848 555		France	06-18-2004				X			
	2004/074285		PCT	09-02-2004				X			
	0 254 588		Europe	01-27-1988				X			

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	Bunpei Kakinoki et al. "General Pharmacological Properties of the New Proton Pump Inhibitor (+)-5-Methoxy-2-[[[(4-methoxy-3, 5-dimethylpyrid-2-yl)methyl]sulfinyl]-1H-imidazo[4,5-b]pyridine", Vol. 21, No. 3, 1999, pgs. 179-187.
	International Search Reported dated 30 November 2005

Examiner Signature	/Niloofer Rahmani/	Date Considered	04/01/2008
--------------------	--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/